Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

By A. Decensi, M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, Sara Gandini. Cancer Prevention Research, 2010

907 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/96064e9f2a4f453fb50e0a0aeab4ea86a0de95a2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Goldhirsch
2. W. Wood
3. A. Coates
4. R. Gelber
5. K. Avgerinos
6. B. Thürlimann
7. H. Senn
8. Nikolaos K. Spyrou

Citations in the corpus

• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “Retrospective studies indicate that diabetic patients receiving metformin have a lower incidence of cancer compared with diabetic patients not receiving this agent [44].”
• Obesity and cancer risk: Emerging biological mechanisms and perspectives. (2019, result): “Despite several conflicting results, meta-analyses have shown an overall decrease in cancer risk of about 30% throughout all malignancies, particularly in pancreatic and hepatocellular cancers [243,244].”